Table 2.
Amitriptyline M (SD) | Placebo M (SD) | Time effect | Group effect | Interaction | |
---|---|---|---|---|---|
Primary outcome | |||||
GASE-AD | F (1, 37) = 14.57** | F (1, 37) = 11.27* | F (1, 37) = 14.37** | ||
Baseline | 0.89 (0.88) | 1.10 (1.37) | |||
Acquisition | 4.37 (2.45) | 1.10 (1.59) | |||
Evocation | 2.35 (2.49) | 0.98 (1.51) | |||
GASE-AD-MA | F (1, 37) = 17.31** | F (1, 37) = 27.21** | F (1, 37) = 14.12** | ||
Baseline | 0 (0) | 0 (0) | |||
Acquisition | 3.48 (2.59) | 0.18 (0.51) | |||
Evocation | 1.74 (2.58) | 0.10 (0.45) | |||
Further analyses | |||||
GASE-generic | F (1, 37) = 0.84 | F (1, 37) = 0.23 | F (1, 37) = 2.05 | ||
Baseline | 4.32 (3.68) | 3.75 (3.68) | |||
Acquisition | 5.63 (4.78) | 3.85 (3.69) | |||
Evocation | 3.68 (3.43) | 4.42 (5.49) | |||
GASE-generic-MA | F (0.60, 22.20)a = 5.43* | F (0.60, 22.20)a = 3.88 | F (0.60, 22.20)a = 2.87 | ||
Baseline | 0 (0) | 0 (0) | |||
Acquisition | 1.87 (3.40) | 0.37 (1.09) | |||
Evocation | 0.48 (0.91) | 0.21 (0.90) | |||
GASE-total | F (0.85, 31.48)a = 5.61* | F (0.85, 31.48)a = 2.13 | F (0.85, 31.48)a = 6.11* | ||
Baseline | 5.21 (3.55) | 4.85 (4.80) | |||
Acquisition | 10.00 (5.24) | 4.95 (4.95) | |||
Evocation | 6.03 (4.58) | 5.40 (6.77) | |||
GASE-total-MA | F (0.76, 22.28)a = 14.53** | F (0.76, 22.28)a = 23.45** | F (0.76, 22.28)a = 10.04* | ||
Baseline | 0 (0) | 0 (0) | |||
Acquisition | 5.36 (4.69) | 0.55 (1.57) | |||
Evocation | 2.22 (3.17) | 0.31 (1.34) | |||
GASE-AMI | F (1, 37) = 14.52** | F (1, 37) = 9.13* | F (1, 37) = 15.08** | ||
Baseline | 1.05 (1.13) | 1.40 (1.89) | |||
Acquisition | 5.33 (2.91) | 1.35 (2.11) | |||
Evocation | 2.87 (2.84) | 1.28 (2.41) | |||
GASE-AMI-MA | F (1, 37) = 17.01** | F (1, 37) = 31.54** | F (1, 37) = 14.98** | ||
Baseline | 0 (0) | 0 (0) | |||
Acquisition | 4.06 (2.86) | 0.18 (0.51) | |||
Evocation | 1.89 (2.88) | 0.10 (0.45) |
GASE-AD Antidepressant Composite Score of the Generic Assessment of Side Effects Scale, GASE-AD-MA medication-attributed symptoms of the Antidepressant Composite Score of the Generic Assessment of Side Effects Scale, GASE-generic generic symptoms on the Generic Assessment of Side Effects Scale, GASE-generic-MA medication-attributed generic symptoms on the Generic Assessment of Side Effects Scale, GASE-total all reported side effects as assessed with the Generic Assessment of Side Effects Scale, GASE-total-MA all medication-attributed side effects as assessed with the Generic Assessment of Side Effects Scale, GASE-AMI score of all common side effects of amitriptyline, GASE-AMI-MA score of all medication-attributed common side effects of amitriptyline
*p ≤ .05
**p ≤ .001
aDegrees of freedom have been corrected according to Greenhous-Geisser